Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
03 Febbraio 2022 - 10:05PM
Business Wire
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage
biopharmaceutical company dedicated to delivering targeted
therapies for rare cancers, today announced that the underwriters
of its previously announced underwritten public offering exercised
in full their option to purchase 750,000 additional shares of
common stock at a price of $27.00 per share, before deducting
underwriting discounts and commissions. With this exercise, the
aggregate gross proceeds to Sierra Oncology from the offering were
approximately $155.3 million, before deducting underwriting
discounts and commissions and other offering expenses. The offering
of the additional 750,000 shares closed on February 3, 2022. Sierra
Oncology intends to use the net proceeds of the offering to prepare
for potential commercialization of momelotinib, clinical
development of its other product candidates, research, clinical and
process development and manufacturing of its product candidates,
working capital, and capital expenditures and other general
corporate purposes.
Jefferies and Cantor acted as the joint book-running managers
and representatives of the underwriters for the offering. LifeSci
Capital, Oppenheimer & Co. and H.C. Wainwright & Co. acted
as lead managers for the offering.
A shelf registration statement on Form S-3 relating to the
securities offered in the public offering described above was filed
with the Securities and Exchange Commission (SEC) on November 5,
2021 and declared effective by the SEC on November 12, 2021. A
final prospectus supplement and accompanying prospectus relating to
the offering have been filed with the SEC and are available on the
SEC’s website at www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus may also be obtained by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 821-7388, or by email at
prospectus_department@jefferies.com; or Cantor Fitzgerald &
Co., Attention: Capital Markets, 499 Park Avenue, New York, New
York 10022, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a
quest to deliver targeted therapies that treat rare forms of
cancer. We harness our deep scientific expertise to identify
compounds that target the root cause of disease to advance targeted
therapies with assets on the leading edge of cancer biology. Our
team takes an evidence-based approach to understand the limitations
of current treatments and explore new ways to change the cancer
treatment paradigm. Together we are transforming promise into
patient impact.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220203005935/en/
Investor Contact DeDe Sheel 415.732.9828
dsheel@sierraoncology.com Media Contact Lauren Musto
615.351.7777 lmusto@sierraoncology.com
Grafico Azioni Sierra Oncology (NASDAQ:SRRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sierra Oncology (NASDAQ:SRRA)
Storico
Da Giu 2023 a Giu 2024